SPRO Spero Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRO

Price (delayed)

$1.63

Market cap

$87.81M

P/E Ratio

3.79

Dividend/share

N/A

EPS

$0.43

Enterprise value

$17.02M

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Highlights
The net income has soared by 149% YoY
The EPS has surged by 135% year-on-year and by 10% since the previous quarter
SPRO's quick ratio is up by 23% since the previous quarter but it is down by 8% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://sperotherapeutics.com
Peers: FC IBM DV

Key stats

What are the main financial stats of SPRO
Market
Shares outstanding
53.87M
Market cap
$87.81M
Enterprise value
$17.02M
Valuations
Price to earnings (P/E)
3.79
Price to book (P/B)
0.81
Price to sales (P/S)
0.83
EV/EBIT
0.67
EV/EBITDA
0.66
EV/Sales
0.16
Earnings
Revenue
$103.78M
EBIT
$25.4M
EBITDA
$25.77M
Free cash flow
-$33M
Per share
EPS
$0.43
Free cash flow per share
-$0.63
Book value per share
$2.02
Revenue per share
$1.97
TBVPS
$3.46
Balance sheet
Total assets
$182.39M
Total liabilities
$75.5M
Debt
$5.54M
Equity
$106.89M
Working capital
$94.06M
Liquidity
Debt to equity
0.05
Current ratio
3.53
Quick ratio
4.67
Net debt/EBITDA
-2.75
Margins
EBITDA margin
24.8%
Gross margin
100%
Net margin
22%
Operating margin
20.7%
Efficiency
Return on assets
18.2%
Return on equity
32.6%
Return on invested capital
130.7%
Return on capital employed
17.5%
Return on sales
24.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SPRO stock price

How has the Spero Therapeutics stock price performed over time
Intraday
1.24%
1 week
11.64%
1 month
-8.94%
1 year
-9.94%
YTD
10.88%
QTD
-5.23%

Financial performance

How have Spero Therapeutics's revenue and profit performed over time
Revenue
$103.78M
Gross profit
$103.78M
Operating income
$21.48M
Net income
$22.81M
Gross margin
100%
Net margin
22%
Spero Therapeutics's operating income has soared by 151% YoY
The net income has soared by 149% YoY
SPRO's operating margin has surged by 126% year-on-year
The net margin has surged by 125% year-on-year

Growth

What is Spero Therapeutics's growth rate over time

Valuation

What is Spero Therapeutics stock price valuation
P/E
3.79
P/B
0.81
P/S
0.83
EV/EBIT
0.67
EV/EBITDA
0.66
EV/Sales
0.16
The EPS has surged by 135% year-on-year and by 10% since the previous quarter
The equity has soared by 99% since the previous quarter and by 41% year-on-year
The price to book (P/B) is 70% less than the 5-year quarterly average of 2.7 and 26% less than the last 4 quarters average of 1.1
SPRO's P/S is 95% below its 5-year quarterly average of 15.5 and 25% below its last 4 quarters average of 1.1
SPRO's revenue has soared by 94% YoY and by 34% from the previous quarter

Efficiency

How efficient is Spero Therapeutics business performance
The return on assets has surged by 139% year-on-year
Spero Therapeutics's ROE has soared by 136% YoY
The return on sales has surged by 130% year-on-year
SPRO's ROIC has soared by 121% YoY and by 119% QoQ

Dividends

What is SPRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRO.

Financial health

How did Spero Therapeutics financials performed over time
SPRO's total assets is 142% higher than its total liabilities
SPRO's total assets has soared by 70% QoQ and by 46% YoY
SPRO's total liabilities has surged by 54% year-on-year and by 41% since the previous quarter
The debt is 95% smaller than the equity
The equity has soared by 99% since the previous quarter and by 41% year-on-year
The debt to equity has plunged by 55% from the previous quarter and by 44% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.